We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck KGaA (MKGAF) Q3 Earnings Up Y/Y, 2016 View Intact
Read MoreHide Full Article
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
At its 2016 Capital Market Day, the company provided an update on its objectives up to 2018. Beginning 2017, the company aims to gain approval of one medicine or new indication every year. Merck KGaA expects to generate sales of €4 billion from products that are currently in its pipeline by 2022.
The company’s lead candidate, avelumab, is being evaluated in phase III studies for several cancer indications, in collaboration with Pfizer. Avelumab is currently under review in the EU for the treatment of metastatic Merkel cell carcinoma (MCC).
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s third-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.20, compared to the year-ago figure of 90 cents.
Revenue: The company posted revenues of $4.1 billion in the reported quarter.
Key Stats: Organic sales growth increased 0.9%, driven by Life Science segment. The acquisition of Sigma-Aldrich boosted sales in the reported quarter.
Guidance: For 2016, the company continues to expect net sales in the range of €14.9–€15.1 billion. Backed by Sigma-Aldrich acquisition, the company continues to expect a positive portfolio effect on sales in the low double-digit percentage range. Unfavorable foreign exchange is projected to impact sales by 3–5% due to currency devaluation in Latin America.
Check back later for our full write up on earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck KGaA (MKGAF) Q3 Earnings Up Y/Y, 2016 View Intact
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
At its 2016 Capital Market Day, the company provided an update on its objectives up to 2018. Beginning 2017, the company aims to gain approval of one medicine or new indication every year. Merck KGaA expects to generate sales of €4 billion from products that are currently in its pipeline by 2022.
The company’s lead candidate, avelumab, is being evaluated in phase III studies for several cancer indications, in collaboration with Pfizer. Avelumab is currently under review in the EU for the treatment of metastatic Merkel cell carcinoma (MCC).
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s third-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.20, compared to the year-ago figure of 90 cents.
Revenue: The company posted revenues of $4.1 billion in the reported quarter.
Key Stats: Organic sales growth increased 0.9%, driven by Life Science segment. The acquisition of Sigma-Aldrich boosted sales in the reported quarter.
Guidance: For 2016, the company continues to expect net sales in the range of €14.9–€15.1 billion. Backed by Sigma-Aldrich acquisition, the company continues to expect a positive portfolio effect on sales in the low double-digit percentage range. Unfavorable foreign exchange is projected to impact sales by 3–5% due to currency devaluation in Latin America.
MERCK KGAA Price
MERCK KGAA Price | MERCK KGAA Quote
Check back later for our full write up on earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>